A Spinal Cord Sarcoma With EWSR1::WT1 Fusion Exhibited Ewing Sarcoma‐Like Pattern Rather Than Desmoplastic Small Round Cell Tumor Authors: Chuqian Zeng, Yishan Wang Published: 2026 ABSTRACT ABSTRACTWe received a case of a 22 years old female, with a spinal cord sarcoma. The tumor exhibited a morphology similar to that of a small blue round cell tumor, lack of desmoplastic stroma. Immunohistochemical analysis demonstrated diffusely membranal expression of CD99 and cytoplasmic expression of Desmin, but was negative of NKX2.2. Fluorescence in situ hybridization indicated the EWSR1 gene rearrangement. Next generation sequencing (NGS) identified a gene fusion of EWSR1(E9)::WT1(E8). The fusion gene was confirmed by RNA NGS as well. There was a challenge on diagnosis whether should it be diagnosed as Ewing sarcoma‐like tumor or DSRCT. Conclusion: The EWSR1::WT1 fusion tumor has a wide spectrum of diseases. The morphology may be associate with specific gene breakage site, or/and tissue specificity. Final diagnosis should be rendered based on comprehensive correlation of clinical presentation, morphology, immunophenotype, and molecular finding.Keywords: desmoplastic small round cell tumor, Ewing sarcoma‐like, EWSR1::WT1 fusion, next generation sequencing, spinal cord sarcoma Introduction EWSR1::WT1 fusion is regarded as characteristic gene fusion of desmoplastic small round cell tumor (DSRCT). According to the 5th WHO classification of soft tissue and bone tumors, DSRCT is a malignant mesenchymal neoplasm composed of small round cells associated with prominent stromal desmoplasia, polyphenotypic differentiation, and EWSR1::WT1 fusion. But it lacks of secondary mutations but a significant number of copy number alterations. It is hypothesized that the N‐terminal domain of EWSR1 acts as a transcriptional activator, while the zinc finger domains of WT1 binds regulatory elements in target genes [1]. Recent analyzes of mutational profiles revealed the deregulation of genes related to immune response, epithelial–mesenchymal transition (EMT), and the DNA damage response (DDR) in DSRCT [2, 3]. In the 5th WHO classification of soft tissue and bone tumors, undifferentiated small round cell tumor comprises Ewing sarcoma, round cell sarcoma with EWSR1‐non‐ETS fusion, CIC‐rearranged sarcoma, sarcoma with BCOR genetic alterations [4]. Ewing sarcoma is a small cell sarcoma with gene fusions involving one member of the FET family (usually EWSR1) and a member of the ETS family [4]. In this category, small round cell sarcoma with EWSR1‐non‐ETS fusion include the EWSR1::NFATC2‐fusion and the EWSR1::PATZ1‐fusion sarcoma. Pitfalls in ES diagnosis include aberrant expression of immunohistochemical markers. Neuroendocrine markers and/or desmin are rarely seen, but keratin expression may occur in up to 25% of cases [5]. It was discovered that EWSR1 is rearranged in clear cell sarcoma, angiomatoid fibrous histiocytoma, extra‐skeletal myxoid chondrosarcoma and hyalinising clear cell carcinoma, among others [6]. In our case, the spinal cord sarcoma exhibited Ewing sarcoma‐like pattern lack of desmoplastic stromal, with EWSR1::WT1 fusion. Cordier F reported a case of an undifferentiated sarcoma of the bone with a round to epithelioid cell phenotype harboring a novel EWSR1‐SSX2 fusion. The author thought it could be a new member belonging to the heterogeneous group of round cell sarcomas with EWSR1‐non‐ETS fusion [7]. EWSR1 fusions are present in tumor types that show morphological overlap with one another. Specific EWSR1 fusion genes has led to some confusion and controversy in the tumor classification system [6]. The reports reminded us that our case might be a situation like this, because our case displayed a pattern similar to Ewing sarcoma rather than DSRCT, and strongly co‐expressed CD99 and desmin. Case Description We received a case of a 22 years old female, suffering from progressive weakness and limping in both lower extremities, as well as low back pain in More than twenty days. She had accepted magnetic resonance imaging. The spinal cord was thickened, showed irregular long T1 and T2 signal shadows at the T12‐L1 level, multiple small cystic changes within it, measuring approximately 5 cm long. Enhanced scanning revealed uneven enhancement (as shown in Figure 1). In addition, abnormal fusiform signal shadows were observed at the T5/6 and T8/9 vertebrae. Multiple small nodular with abnormal signal shadows could be seen on the surface of the dura mater and spinal cord, and uneven enhancement while enhanced scanning. It demonstrated heterogeneous hyperintensity on sagittal and axial T2WI with multiple internal cystic areas, and obscure boundary. She underwent a tumor resection for pathological examination. Microscopically, the tumor exhibited a diffuse growth pattern with focal necrosis. The neoplasm consisted of small round cells demonstrating morphological uniformity (as shown in Figure 2A). The tumor cells displayed scant cytoplasm, resulting in a high nuclear‐to‐cytoplasmic ratio. Nuclei were irregular with finely stippled (‘powdery’) chromatin, inconspicuous nucleoli (as shown in Figure 2B). Brisk mitotic activity (8~18 mitoses/10 HPF) was found. There was few fibrous stromal. (A) The tumor exhibited a diffuse growth pattern. There was few fibrous stromal. H&E, x100. (B) The neoplasm consisted of small round cells demonstrating morphological uniformity. The tumor cells displayed scant cytoplasm, resulting in a high nuclear‐to‐cytoplasmic ratio. Nuclei were irregular with finely stippled (‘powdery’) chromatin, inconspicuous nucleoli. Brisk mitotic activity (8~18 mitoses/10 HPF) were found. H&E, x400. (C) CD99 was diffusely positive on cytomembrane. IHC x200. (D) Cytoplasmic expression of Desmin. However, part of tumor cells expressed Desmin with dot‐like pattern. IHC x200. Immunohistochemical analysis demonstrated diffusely membranal expression of CD99 and cytoplasmic expression of Desmin (as shown in Figure 2C,D). However, part of tumor cells expressed Desmin with dot‐like pattern. P53 is diffusely positive. Focal weak expression was observed for Pan‐CK (as shown in Figure 3C), FLI‐1, BCOR, MyoD1, Synaptophysin, EMA. Normal expression was detected for INI‐1, SMARCA4, H3k27me3 without any loss. The tumor was negative for NKX2.2 (as shown in Figure 3A), C‐myc, S‐100 (as shown in Figure 3B), Sox10, SS18, P63, WT1(N‐terminal), Chromogranin A, Myogenin, SSTR2, olig2, GFAP, CD3, CD20, CD30, H3K27M, SALL4, OCT3/4, HMB45, Melan‐A, Branchyury and CD34. The Ki‐67 proliferative index was approximately 50%. (A) NKX2.2 was negative. IHC x200. (B) S100 was negative. IHC x200. (C) Focal weak expression was observed of Pan‐CK. IHC x200. Fluorescence in situ hybridization (EWSR1 Break Apart Probe, Ibp) showed split signals, which indicated the EWSR1 gene rearrangement (as shown in Figure 4A). (A) Fluorescence in situ hybridization showed red‐green split signals of EWSR1 Break Apart Probe. (B) Next generation sequencing (NGS) identified a gene fusion of EWSR1::WT1 that fused exon 9 of EWSR1 (chr22:29687620) with exon 8 of WT1 (chr11:32416078). (C) RNA NGS detected the transcription product of EWSR1(E9)::WTI(E8) fusion gene. Next generation sequencing (NGS) identified a gene fusion of EWSR1::WT1 that fused exon 9 of EWSR1 (chr22:29687620) with exon 8 of WT1 (chr11:32416078) (as shown in Figure 4B). The fusion gene was confirmed by RNA NGS with the MAP Solid Tumor Fusion Gene Detection Kit on lllumina NovaSeq. 6000 (as shown in Figure 4C). In addition to the fusion gene, it was detected TP53 mutation, LOH of CDKN2A and TP53, homozygous deletion of PTCH1 and FANCC. Analysis of whole‐genome copy number variation (CNV) and loss of heterozygosity (LOH) revealed copy number gains in the following chromosomal regions: 4q, 5q35.2 → q35.3, 8p23.3 → q13.2, 8q24.3, 17q, and Xq11.2 → q13.1; copy number losses in the following regions: 3p, 4p, chromosome 9 (with deletions of CDKN2A/B, FANCC, and PTCH1), 14q11.2 → q24.3, 16q11.2 → q21, chromosome 17 (with TP53 deletion), 21q11.2 → q21.3, and Xq13.2 → q28; and CN‐LOH in the following regions: 8q13.3 → q21.3, chromosome 13, and 16q22.1 → q24.3. Discussion Combined with morphology and immunohistochemical analysis, we had excluded several diagnoses, included in poorly differentiated synovial sarcoma, alveolar rhabdomyosarcoma with solid pattern, mesenchymal chondrosarcoma, neuroendocrine neoplasm and lymphoma. Although the tumor was composed of small round cells with scarce mesenchyme, a pattern similar to Ewing sarcoma. DNA and RNA NGS detected the fusion gene of EWSR1::WTI, and immunohistochemistry showed negative expression of the NKX2.2 antibody; these findings do not support a diagnosis of Ewing sarcoma. It was a big challenge for us to diagnosed as desmoplastic small round cell tumor (DSRCT) or Round cell sarcoma with EWSR1‐non‐ETS fusion. Referred to references, many cases which demonstrated unlike the classical morphology of DSRCT were reported (as shown in Table 1). These cases harbored EWSR1::WT1 fusion, but lack of, or few of desmoplastic stroma. The locations of lesions included abdominal cavity, axillary soft tissue, retroperitoneal soft tissue, female genital tract, cauda equina. The patients were 12–85 years old, respectively. They showed a wide morphological spectrum, consisted of epithelioid cells, spindle shaped cells, small round cells [8, 9, 10, 11, 12, 13, 14, 15, 16]. Some of the authors considered these cases as a variant of DSRCT with atypical morphology. Others thought of a new entity or subsets of discrete entities with EWSR1::WTI fusion, rather than DSRCT, according to morphology [8, 9, 10, 11, 12, 13, 14, 15, 16]. Table 1Clinicopathological, immunohistochemical, and molecular features of reported EWSR1–WT1 fusion‐associated tumors which lack/ few of desmoplastic stroma.AuthorAge/sexLocationHistopathologyIHCGene alterationOutcomeAli et al. 8 16/FAbdominal cavityUniform small round cells arranged in sheet‐like architectureDiffused expression: WT1 (carboxy terminal); focal expression: neuron‐specific enolase (NSE)N/AN/AFelix et al. 9 26/MPeritoneum of the left lower abdomenComposed of monotonous small round to polygonal cells growing in small, confluent nests, trabeculae, and strandsDiffuse and strong cytoplasmic expression of DesminFusion that fused exon 7 of EWSR1 with exon 8 of WT1No recurrent 10months after resectionKihara et al. 10 51/MAbdominal cavitySmall round cells arranged in solid patternDiffused expression: Desmin, BCL2, CD99; focal expression: AE1/AE3, CAM5.2, NSE, Syn, SMA, actinFusion of EWSR1 exon 7 and WT1 exon 8N/AAGNES S et al. 11 15/FRetroperitoneal massSmall primitive cells forming well‐defined nestsDiffused expression: Desmin, vimentin; focal expression: keratin, NSE, and CD99.Fusion of EWSR1 exon 9 and WT1 exon 8N/AMagro et al. 12 12/MAbdominal cavitySpindle cells arranged into short, intersecting fasciclesExpression: vimentin, desmin, WT‐1 (C‐terminus antibodies) and EMAFusion of EWSR1 exon 9 and WT1 exon 7Died 9 months after the diagnosisAlaggio et al. 13 AdolescentAbdominal cavitySpindle cells arranged in sheets or in fasciclesExpression: Cytokeratins SMA, desmin, and actinRT‐PCR analysis showed an EWS‐WT1 fusion transcriptCase1 alived at 3 years after diagnosisCase2 alived at 13 years after diagnosisZhang et al. 14 17/FAbdominal cavitySmall round cells lining microcystic structures, forming pseudoacini and trabeculae and cords.Expression: vimentin, desmin, SMA, Syn, NSE, Bcl‐2 and WT1N/AN/ASchoolmeester et al. 15 46/FCervixMostly were spindled cells arranged in a mixture of sheet‐like and fascicular architectureDiffused expression: Desmin; focal expression: AE1/AE3Fusion of EWSR1 exon 9 and WT1 exon 8No recurrent 9 months after diagnosis.30/FLarge mass involving left ovary, myometrium, retroperitoneum, peritoneum, uterine serosaComposed of sheets and fascicles of cells with cystic changeDiffused expression: Desmin; focal expression: AE1/AE4, SMAFusion of EWSR1 exon 10 and WT1 exon 7, in addition, WT1 had a 12 bp in‐frame deletion.Lymph node metastasis 7 months after diagnosis20/FMass centered in the left vaginal fornixComposed of predominantly fascicular of spindle cellsDiffused expression: Desmin, WT1; focal expression: AE1/AE5, SMAFusion of EWSR1 exon 9 and WT1 exon 9Alived at three and a half years after diagnosisUd Din et al. 16 34/ML4 nerve rootComposed of small round cells, arranged in nests and cords, focally show rosette‐like structuresDiffused expression: Desmin, SMA; focal expression: CD99, NeuN,A fusion sequence between exon 7 of EWSR1 and exon 8 of WT1Alived a 9 months after surgeryAbbreviations: AE1/AE3, cytokeratin AE1/AE3; BCL2, B‐cell lymphoma 2; CAM5.2, cytokeratin CAM5.2; CD99, cluster of differentiation 99; EMA, epithelial membrane antigen; EWSR1, Ewing sarcoma breakpoint region 1; IHC, immunohistochemistry; N/A, not available; NSE, neuron‐specific enolase; RT‐PCR, reverse transcription‐polymerase chain reaction; SMA, smooth muscle actin; Syn, synaptophysin; WT1, Wilms tumor 1. Clinicopathological, immunohistochemical, and molecular features of reported EWSR1–WT1 fusion‐associated tumors which lack/ few of desmoplastic stroma. Abbreviations: AE1/AE3, cytokeratin AE1/AE3; BCL2, B‐cell lymphoma 2; CAM5.2, cytokeratin CAM5.2; CD99, cluster of differentiation 99; EMA, epithelial membrane antigen; EWSR1, Ewing sarcoma breakpoint region 1; IHC, immunohistochemistry; N/A, not available; NSE, neuron‐specific enolase; RT‐PCR, reverse transcription‐polymerase chain reaction; SMA, smooth muscle actin; Syn, synaptophysin; WT1, Wilms tumor 1. The tumor presented in this case was not DSRCT for several reasons. DSRCT mainly develops in abdominal cavity. In our case, the female patient developed tumor in spinal cord, any desmoplastic stroma can be seen under microscope. Due to microscopic morphology and lesion location, we preferred to consider our case as small cell sarcoma with EWSR1‐non‐ETS fusion, even it was EWSR1::WT1 gene fusion. Interestingly, it co‐expressed CD99 and Desmin strongly. Ultimately, this study lends strong support to the notion that even the specific EWSR1::WT1 fusion of DSRCT occurs in other tumor types and therefore is not strictly disease‐defining. It probably encompasses tumor entities with different clinical, morphologic, and immunohistochemical characteristics. EWSR1::WT1 chimeras have been described in which exons 7–11 of the EWSR1 gene are fused to exon 8–10 of the WT1 gene. Each of these fusion proteins may include or lack a Lys‐Thr‐Ser (KTS) insert located between zinc fingers 3 and 4 of the WT1 portion of the chimera [1, 2, 17, 18, 19, 20]. The alternative splicing different isoforms of the fusion protein maybe an essential clue accounts for morphological diversity of non‐DSRCT EWSR1::WT1 fusion tumor. We noted a case similar to ours, which AGNES S. CHAN reported in 1999 [11]. A 15‐year‐old female presented with a retroperitoneal mass. The patient underwent needle biopsy of the mass. The tumor was composed of small, uniform cells with hyperchromatic nuclei without identifiable nucleoli. Tumor cells showed no differentiation or particular architectural arrangements, without desmoplastic reaction. The tumor cells stained strongly for desmin, and focally for keratin, neuron‐specific enolase, and CD99. No staining for WT1 was noted. RT‐PCR sequencing showed an in‐frame fusion of EWSR1 exon 9 to WT1 exon 8. The same gene breakage site resulted in similar fusion protein. It may indicate similar tumor‐driving mechanism, and then show a similar microscopical pattern. The alternative splicing different isoforms of the fusion protein is responsible for heterogeneity of EWSR1::WT1 fusion tumor. Schoolmeester J et al. reported two cases occurring in female genital tract. Both of them had EWSR1(E9)::WT1(E8) gene fusion like ours [15]. The neoplastic cells were spindled for the most part, were smaller and more epithelioid in some portions, arranging in mainly sheets and fascicles, occasionally nested and corded architecture. The morphology was not similar to ours. We supposed that the distinction on morphology may be associate with tissue specificity, in addition to specific gene breakage site. An EWSR1‐WT1 fusion alone is not sufficient for a reliable diagnosis of DSRCT, since the EWSR1::WT1 fusion tumor has a wide spectrum of diseases. Final diagnosis should be rendered cautiously and appropriately based on comprehensive correlation of clinical presentation, morphology, immunophenotype, and molecular findings. It is advisable to include comments addressing prognostic stratification and follow‐up management recommendations when applicable. Author Contributions Chuqian Zeng: conceptualization, study design, data analysis, methodology, visualization, software, writing, review, supervision. Yishan Wang: data Acquisition, performed experiments, collected data, review. All authors have read and approved the final manuscript and agree to be accountable for all aspects of this work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Funding The authors have nothing to report. Consent Written informed consent was obtained from the patient included in the study. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.